Timothy Mok, PharmD, BCPS, BCOP

Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP, close the discussion with key takeaways for payers to consider related to ruxolitinib and insights on future research.

Gabriela Hobbs, MD, describes characteristics of the patient population included in the MAJIC-PV study, and analyzes best available therapies received in the comparator arm.

Experts on polycythemia vera provide a comprehensive overview of the objectives and study design of the MAJIC-PV clinical trial, highlighting key endpoints.